Core Viewpoint - MCTA investors have the opportunity to lead a securities fraud lawsuit against Charming Medical Limited with the Schall Law Firm [1] Group 1 - The lawsuit is focused on allegations of securities fraud involving Charming Medical Limited [1] - The Schall Law Firm is representing MCTA investors in this legal action [1] - This case presents a potential opportunity for investors to seek redress for alleged financial misconduct [1]

Core Viewpoint - A securities fraud class action lawsuit has been filed against Charming Medical Limited on behalf of investors who acquired its securities during the specified class period [1] Group 1 - The lawsuit pertains to investors who purchased or acquired Charming Medical Limited securities between October 10, 2025, and November 12, 2025 [1] - Investors have until February 17, 2026, to file a lead plaintiff motion [1]

Core Viewpoint - Class action lawsuits have been filed on behalf of shareholders of several publicly-traded companies, highlighting allegations of materially false and misleading statements made by the companies regarding their business operations and prospects [1]. Group 1: Integer Holdings Corporation (NYSE: ITGR) - The class period for Integer Holdings Corporation is from July 25, 2024, to October 22, 2025, with a lead plaintiff deadline of February 9, 2026 [2]. - Allegations include that Integer overstated its competitive position in the EP manufacturing market and mischaracterized its EP devices as long-term growth drivers, despite experiencing a deterioration in sales [2]. Group 2: F5, Inc. (NASDAQ: FFIV) - The class period for F5, Inc. is from October 28, 2024, to October 27, 2025, with a lead plaintiff deadline of February 17, 2026 [3]. - The complaint alleges that F5 was involved in a significant security incident that jeopardized client security and the company's future prospects, leading to misleading statements about its business [3]. Group 3: SLM Corporation (NASDAQ: SLM) - The class period for SLM Corporation is from July 25, 2025, to August 14, 2025, with a lead plaintiff deadline of February 17, 2026 [4]. - Allegations state that SLM experienced a significant increase in early-stage delinquencies and overstated the effectiveness of its loss mitigation programs, resulting in misleading statements about its business stability [4]. Group 4: Charming Medical Limited (NASDAQ: MCTA) - The class period for Charming Medical Limited is from October 10, 2025, to November 12, 2025, with a lead plaintiff deadline of February 17, 2026 [5]. - The complaint alleges that Charming was involved in a fraudulent stock promotion scheme and that insiders facilitated share dumping during a price inflation campaign, leading to misleading public statements [5][6].

Core Viewpoint - A class action has been filed on behalf of investors who purchased Charming Medical, Limited (NASDAQ: MCTA) securities between October 10, 2025, and November 12, 2025, indicating potential legal issues for the company [1]. Company Overview - Charming Medical, Limited aims to enhance quality of life by integrating Traditional Chinese Medicine (TCM) wellness practices with modern technology [1].

Core Viewpoint - A class action lawsuit has been filed against Charming Medical Limited (NASDAQ: MCTA) due to allegations of securities fraud during a specific class period from October 10, 2025, to November 12, 2025, with a deadline for lead plaintiff motion set for February 17, 2026 [1][4]. Group 1: Lawsuit Details - The lawsuit alleges that Charming Medical Limited made materially false and misleading statements and failed to disclose adverse facts about its business and operations [4]. - Specific allegations include involvement in a fraudulent stock promotion scheme using social media misinformation and impersonation of financial professionals [4]. - It is claimed that insiders used offshore accounts to facilitate the dumping of shares during a price inflation campaign, and that the company's public statements omitted mention of false rumors and artificial trading activity [4]. Group 2: SEC Involvement - On November 11, 2025, the SEC halted trading of Charming securities due to potential manipulation linked to social media recommendations aimed at inflating the stock price and trading volume [3].

Core Viewpoint - A class action lawsuit has been filed against Charming Medical Limited (NASDAQ: MCTA) on behalf of shareholders who purchased securities during the specified Class Period, alleging securities fraud related to misleading statements and undisclosed adverse facts about the company's operations and business prospects [1][4]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of shareholders who bought Charming Medical Limited securities between October 10, 2025, and November 12, 2025, with a deadline for filing a lead plaintiff motion set for February 17, 2026 [1]. - The lawsuit alleges that the defendants made materially false and misleading statements and failed to disclose significant adverse facts about the company's business and operations [4]. Group 2: Allegations of Fraud - The complaint claims that Charming was involved in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [4]. - It is alleged that insiders or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [4]. - The company's public statements and risk disclosures reportedly omitted any mention of false rumors and artificial trading activity that influenced the stock price, rendering the defendants' positive statements materially misleading [4]. Group 3: SEC Involvement - On November 11, 2025, the SEC issued an order to halt trading of Charming securities due to potential manipulation linked to social media recommendations aimed at artificially inflating the stock price and trading volume [3].

Core Viewpoint - A federal securities class action has been filed against Charming Medical Ltd. for alleged violations of the Securities Exchange Act of 1934, following a significant and artificial increase in its stock price during the class period from October 21, 2025, to November 12, 2025 [1][2]. Group 1: Allegations and Stock Performance - The lawsuit claims that Charming Medical's stock price surged from $4.00 to a high of $29.36 without any fundamental news, indicating potential market manipulation [2]. - Plaintiffs allege that the price increase was driven by a fraudulent social-media-based stock promotion scheme, where impersonators posed as financial advisors to promote the stock with unsupported claims [3]. - Trading in Charming Medical securities was suspended in November 2025, revealing the artificial nature of the stock price increase and leading to investor losses [4]. Group 2: Legal Proceedings and Investor Actions - The proposed class includes all individuals and entities who purchased Charming Medical securities during the class period and suffered damages, excluding defendants and their affiliates [4]. - Investors have until February 17, 2026, to seek appointments as lead plaintiff in the class action [1][4]. Group 3: Law Firm Background - Wolf Haldenstein Adler Freeman & Herz LLP, founded in 1888, specializes in securities litigation and has a long history of advocating for investors who have suffered financial harm due to misrepresented statements [6]. - The firm encourages affected investors to contact them for assistance in the ongoing investigation [6].

Core Viewpoint - Charming Medical Limited is facing a class action lawsuit due to allegations of stock price manipulation through a fraudulent promotion scheme, which led to a significant and unjustified increase in its stock price [3]. Group 1: Company Overview - Charming Medical Limited operates in the wellness sector, integrating Traditional Chinese Medicine (TCM) with modern technology to offer wellness and beauty services and products for both women and men [3]. - The company's stock is traded on NASDAQ under the symbol "MCTA" [3]. Group 2: Stock Price Manipulation Allegations - The complaint against Charming Medical alleges violations of the Securities Act due to the suspension of its stock in November 2025, following an artificial price surge [3]. - Prior to the suspension, Charming's share price rose dramatically from the IPO price of $4.00 to an all-time high of $29.36 per share, without any fundamental news to justify this increase [3]. - Investigations revealed that the stock price was inflated by a social-media-based promotion scheme involving impersonators posing as legitimate financial advisors, which created a buying frenzy among retail investors [3]. Group 3: Legal Actions and Investor Support - The Portnoy Law Firm is advising investors who purchased Charming Medical securities between October 21, 2025, and November 12, 2025, to file a lead plaintiff motion by February 17, 2026 [1]. - Investors are encouraged to contact the Portnoy Law Firm for a complimentary case evaluation and to discuss options for pursuing claims to recover losses [2].

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Charming Medical Limited ("Charming†or the "Company†) (NASDAQ: MCTA) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CHARMING MEDICAL LIMITED (MCTA), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happen. ...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Charming Medical Limited ("Charming†or the "Company†) (NASDAQ: MCTA) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CHARMING MEDICAL LIMITED (MCTA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal. ...